Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.

[1]  H. Kantarjian,et al.  The role of gemtuzumab ozogamicin in acute leukaemia therapy , 2005, British journal of haematology.

[2]  I. Bernstein,et al.  Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence , 2005, Cancer.

[3]  A. Trontell.  The RADAR project and the FDA. , 2005, JAMA.

[4]  I. Bernstein,et al.  Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. , 2005, Blood.

[5]  Matthew H Samore,et al.  The Research on Adverse Drug Events and Reports (RADAR) project. , 2005, JAMA.

[6]  A. Trontell.  Expecting the unexpected--drug safety, pharmacovigilance, and the prepared mind. , 2004, The New England journal of medicine.

[7]  L. Peterson,et al.  Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  A. Rohatiner,et al.  A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia , 2003 .

[9]  E. Estey,et al.  Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia , 2003, Cancer.

[10]  G. Garcia-Manero,et al.  Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. , 2003, Leukemia research.

[11]  E. Estey,et al.  Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. , 2003, Leukemia research.

[12]  E. Estey,et al.  Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia , 2003, Cancer Chemotherapy and Pharmacology.

[13]  P. Richardson,et al.  Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. , 2003, Blood.

[14]  W. Tissing,et al.  Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. , 2003, Blood.

[15]  H. Kantarjian,et al.  Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high‐risk myelodysplastic syndromes , 2003, Cancer.

[16]  E. Estey,et al.  Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia , 2002, Cancer Chemotherapy and Pharmacology.

[17]  A. Gewirtz,et al.  Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease , 2002, Bone Marrow Transplantation.

[18]  E. Estey,et al.  Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. , 2002, Blood.

[19]  G. McDonald,et al.  Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. , 2002, Blood.

[20]  G. McDonald.  Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). , 2002, Clinical lymphoma.

[21]  P. Richardson,et al.  Hepatic Veno-Occlusive Disease following Hematopoietic Stem Cell Transplantation , 2001, Acta Haematologica.

[22]  E. Estey,et al.  Mylotarg™ (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation , 2001, Cancer.

[23]  I. Bernstein,et al.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  X. H. Chen,et al.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  A. Wood,et al.  Thrombotic thrombocytopenic purpura and clopidogrel--a need for new approaches to drug safety. , 2000, The New England journal of medicine.

[26]  E. Estey,et al.  Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia , 2002, Cancer Chemotherapy and Pharmacology.